On December 2, the Beijing Economic and Technological Development Zone Management Committee officially signed a cooperation memorandum with Sanofi. Sanofi will invest approximately 1 billion euros to establish a new insulin production base in Beijing Economic and Technological Development Zone, enhancing local end-to-end production capabilities for insulin to meet the medication needs of local diabetic patients. This will be Sanofi's fourth production and supply base in China. It is reported that the newly established insulin production base is the first time a multinational pharmaceutical company has laid out the production of biopharmaceutical active pharmaceutical ingredients domestically.